Medicine Program, Kasturba Medical College Mangalore, Karnataka, India.
Hum Vaccin Immunother. 2022 Dec 31;18(1):2033541. doi: 10.1080/21645515.2022.2033541. Epub 2022 Feb 22.
The recent article "Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?" published on December 2 is thought provoking. The authors highlight critical disparities in the manufacture and distribution of COVID-19 vaccines although over 350 COVID-19 vaccine candidates are reported to be in the preclinical and clinical development phase. The history of vaccine research and production in India is as ancient as the history of vaccines themselves. Interestingly, vaccine manufacture that was once monopolized by India, declined in its productivity and stature, primarily for the lack of a strategic vision. The recent approval of COVAXIN, designed and developed in India, for emergency use by the World Health Organization is significant for a huge and diverse developing country such as India, especially to transform a weak regulatory system, and enhance public trust.
最近发表在 12 月 2 日的文章《探索针对 SARS-CoV-2 及其变体的 COVID-19 疫苗候选物：我们的立场和前进方向》发人深省。尽管已有超过 350 种 COVID-19 疫苗候选物处于临床前和临床开发阶段，但作者强调了 COVID-19 疫苗制造和分发方面存在的重大差异。印度的疫苗研究和生产历史与疫苗本身一样悠久。有趣的是，曾经由印度垄断的疫苗制造，由于缺乏战略眼光，其生产力和地位都有所下降。印度设计和开发的 COVAXIN 最近被世界卫生组织批准紧急使用，这对印度这样一个庞大而多样化的发展中国家来说意义重大，特别是为了改变薄弱的监管体系，增强公众信任。
